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Abstract 
The objective of this study was to investigate the clinicopathological characteristics and 
survival outcomes of Paget disease(PD)，Paget disease concomitant infiltrating duct 
carcinoma(PD-IDC) and Paget disease concomitant intraductal carcinoma(PD-DCIS). We identified 
501,631 female patients from 2000 to 2013 in the Surveillance, Epidemiology, and End Results 
(SEER) database. These identified patients included PD patients (n=469), PD-IDC patients(n=1832), 
PD-DCIS patients (n=1130) and infiltrating ductal carcinoma (IDC) (n=498,076). Then we 
compared the clinical characteristics of these patients with those who were diagnosed with IDC 
during the same period. The outcomes of these subtypes of breast carcinoma were different. Based 
on the overall survival, the PD-IDC patients had the worst prognosis (5-year survival rate=84.1%). 
The PD-DCIS had the best prognosis (5-year survival rate=97.5%). Besides, among Paget disease 
patients, the one who was married had a better prognosis than who were not. And according to our 
research, the marital status was associated with the hormone receptor status in patients with 
PD-IDC. Among three subtypes of Paget disease, patients with PD-IDC had the worst prognosis. 
Besides, patients who were unmarried had worse outcomes. And the marital status of PD-IDC 
patients is associated with hormone status. The observation underscores the importance of 
individualized treatment. 
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Introduction 
 
Breast cancer is the most common cancer in woman across the world. According to the WHO 
experts in the world each year there are revealed from 800,000 up to 1 million new cases of breast 
cancer1. Paget disease is a rare form of breast cancer that occurs in the mouth of the excretory ducts 
of the nipple. This rare abnormality occurs in 0.5-5% of all cases of breast cancer2. PD is 
characterized by an ulcerated, ulcerated, crusted, or scaling lesion on the nipple that can extend to 
the areola3. Paget’s disease of the nipple is characterized by histopathological infiltration of 
neoplastic cells with glandular features in the epidermal layer of the nipple-areolar complex. The 
pathologic mechanism of PD is still unclear. However, there are two kinds of explanation of the 
pathologic origin of the Paget disease-epidermotropic and transformation theory4, 5
 
. The former one 
considered that the cells came from the underlying ductfal tumor and then move along the 
lactiferous ducts to the nipple. And the other theory suggested that the cells were in situ in the major 
lactiferous sinuses. 
Characterized by malignant crusting or ulceration of the nipple, Paget disease can present in 
one of three ways. The first one is in conjunction with an underlying invasive cancer. The second 
one is in conjunction with underlying ductal carcinoma in situ(DCIS). The last one is alone without 
any underlying invasive breast carcinoma or DCIS6. The Paget disease can be treated by central 
lumpectomy with breast conservation. However, the prognosis of the PD is not well. IDC is the 
most common breast carcinoma subtype during the world. Recent study has suggested that patients 
with Paget disease conjunction with invasive cancer had worse prognosis7. Nevertheless, study 
about all these three kinds of PD is not being researched. And study on relationship between PD 
and the IDC is rare. Previous study described that Paget disease alone without an underlying cancer 
is rare and it presents at most 8% of patients with Paget disease8
Married persons enjoy overall better health and increase life expectancy compared the 
unmarried(divorced, separated, never married)
. 
9,
 
10
. Previous studies have indicated a survival 
advantage for married persons living with cancer11-13. And a research found that married men and 
women with cancer to have a 15% reduced risk of death14. We compared with unmarried men and Au
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women in different subtypes of Paget disease. Besides the different outcomes in unmarried patients, 
we found the correlation between the marital status and the hormone status and the human 
epidermal growth factor receptor II, which can guide the individualized treatment in clinic. 
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Results 
 
Clinicopathological characteristics of PD 
 
Overall 447401 patients who were diagnosed with breast carcinoma were evaluated. We 
evaluated 447401 patients with breast cancer. Among these patients, 443970 were with infiltrating 
ductal breast carcinoma, 469 were with mammary Paget disease, 1832 were with Paget disease with 
infiltrating ductal carcinoma and 1130 were with Paget disease with intraductal carcinoma. The 
demographics and clinicopathological characteristics of PD, PD-IDC, PD-DCIS were compared 
with IDC. And the results were summarized in Table 1. Using the Pearson chi-square test, for PD 
and IDC, the significant variables were age(p<0.001), marital status(p<0.001), laterality(p<0.001), 
tumor size(p<0.001), lymph node status(p<0.001), Grade(p<0.001), AJCC stage(p<0.001), ER 
(oestrogen receptor) status(p<0.001), PR (progesterone receptor) status(p<0.001), HER2 (human 
epidermal growth factor receptor 2) status(p<0.001) and whether had radiation treatment(p<0.001). 
For PD-IDC and IDC, the significant characteristics were race(p=0.011), marital status(p<0.001), 
tumor size(p<0.001), lymph node status(p<0.001), Grade(p<0.001), AJCC stage(p<0.001), ER 
status(p<0.001), PR status(p<0.001), HER2 status(p<0.001) and whether had radiation 
treatment(p<0.001). For PD-DCIS and IDC, the considerable characteristics were age(p<0.001), 
marital status(p<0.001), tumor size(p<0.001), Grade(p<0.001), AJCC stage(p<0.001), ER 
status(p<0.001), PR status(p<0.001), HER2 status(p<0.001) and whether had radiation 
treatment(p<0.001). 
The Table 2 presents the distribution of characteristics of women with breast cancer stratified 
by marital status. For patients with PD, the clinicopathologic characteristics were age at diagnosis 
(p=0.002), race (p=0.027), laterality (p=0.004), tumor size (p<0.001), lymph node status (p=0.001) 
and radiation situation (p<0.001). The hormone status did not have statistical significance. However, 
according to the analyses, patients who were diagnosed with PD-IDC had different statistical 
factors. The hormone status had statistical significance - ER status (p=0.01), PR status (p=0.006) 
and HER2 status (p=0.025). Meanwhile, for patients with PD-DCIS, the associations were different 
again. Among the three hormone, only HER2 had statistical significance (p=0.01). Other 
characteristics were age (p<0.001), race (p=0.012) and AJCC stage (p<0.001). Be differ from the Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
other two subtypes, the marital status of PD-DCIS patients had no significant correction with the 
radiation status. 
 
Comparison of Survival between three subtypes of Paget disease and IDC 
 
 
Utilizing the Kaplan-Meier method, we analyzed all these four subtypes (PD, PD-IDC, 
PD-DCIS and IDC) of mammary carcinoma. On the basis of the OS, the different outcomes of four 
subtypes of breast carcinoma were shown distinctly in Figure1. Patients with PD-DCIS had the best 
prognosis with a 5-year OS 83.6%. The one worse than the PD-DCIS was IDC. The 5-year OS of 
patients with IDC was 81.1%. Then the next one was PD. The 5-year OS of patients with PD was 
72.9%. The one with worst outcomes was PD-IDC，whose 5-year OS was 71.4%. 
Then, we analyzed the cases utilizing the DSS and the comparison of different kinds of mammary 
cancer was shown in Figure2. The PD-DCIS patients had the best prognosis with a 5-year survival 
rate of 98.2%. The worse one was patients with PD. Its 5-year survival rate was 92.4%. Then was 
patients with IDC whose 5-year survival rate was 91%. And patients who were diagnosed with 
PD-IDC had the worst outcomes. Its 5-year survival rate was 84.1%. Apparently, the results of 
the analyses based on the OS and DSS had a little difference. Based on the OS, the results showed 
that the prognosis of PD was worse than IDC. However, based on the DSS, the outcome of the IDC 
was worse than PD. Meanwhile, the prognostic indicators can be found during the univariate 
analysis. 
 
The survival analyses in subtypes of Paget disease 
 
According to the Kaplan-Meier method and compared utilizing the log-rank test, we analyzed 
the Paget disease and its indicator which were associated with the prognosis. The results of the 
analyses were shown in Table3. For PD, indicators which had significance were age at 
diagnosis(p<0.001), marital status(p<0.001), tumor size(p<0.001), lymph node status(p<0.001) and 
AJCC stage(p<0.001). For PD-IDC, the significant indicators were age at diagnosis, marital status, 
tumor size, lymph node status, Grade, AJCC stage and ER status. Meanwhile, the significant 
indicators of PD-DCIS were age at diagnosis(p<0.001), marital status(p<0.001), tumor 
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size(P<0.001), lymph node status(p<0.001), AJCC stage(p<0.001), HER2 status(p<0.001) and 
radiation or not(p=0.007). 
 
Using Cox regression analysis was performed to compute hazard ratios and 95% confidence 
intervals. Choosing the variates which were significant in the univariate analyses, the multivariate 
analyze was performed. And the results were show in Table4. For PD, significant indicators of 
prognosis were age at diagnosis (p=0.005, HR=0.449, 95%CI, 0.257-0.787), race(p=0.014), marital 
status(p<0.001), tumor size, (p=0.033), lymph node status (p<0.001, positive, HR=0.417, 95%CI, 
0.264-0.658) and Grade (p=0.042. The p-value of AJCC stage was larger than 0.05(p=0.203). For 
PD-IDC, variates which had prognostic significance were age at diagnosis (p<0.001, HR=0.347, 
95%CI, 0.283-0.425), marital status(p<0.001), tumor size(p<0.001), lymph node status (p<0.001, 
positive, HR=0.437, 95%CI, 0.366-0.522), Grade(p=0.049), AJCC stage(p<0.001) and ER status 
(p=0.034, positive, HR=0.453, 95%CI, 0.195-1.052). The statistic significant indicators of the 
PD-DCIS patients, were age at diagnosis (p<0.001, HR=0.309, 95%CI, 0.203-0.469), marital status 
(p<0.001, not married, HR=0.504, 95%CI, 0.269-0.945), tumor size (p<0.001), lymph node status 
(p<0.001, positive, HR=0.546, 95%CI, 0.424-0.704), HER2 status (p=0.004, positive, HR=9.502, 
95%CI, 2.758-32.734) and radiation or not p=0.001, yes, HR=2.183, 95%CI, 0.688-6.922). 
 
The association between Paget disease and patient’s marital status 
 
According to the Kaplan-Meier method and compared using the log-rank test, we analyzed the 
Paget disease and the marital status. And the Figure 3 presents the correlation. For patients with PD 
(Figure 3a), the married patients had the best prognosis with a 5-year OS of 85.6%. The unmarried 
patients (included single patients who never married, windowed, divorced and separated patients) 
had worse outcomes with a 5-year OS of 65.2%. Patients whose marital status were unknown had 
the worst diagnosis with a 5-year OS of 48.7%. And the difference between them had statistical 
significance (p<0.001). For Patients who were diagnosed with PD-IDC (Figure 3b), the married 
patients had the best prognosis with a 5-year OS of 78.7%. The next was patients who were 
unmarried with a 5-year OS of 64.1%. For this subtype, the patients whose marital status were 
unknown had the almost similar 5-year OS of 64.9%. And the difference was statistical significant Au
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as well (p<0.001). For patients with PD-DCIS (Figure 3c), the 5-year OS was 90.8% (married), 
76.3% (unmarried) and 76.2% (unknown). 
 
 
 
 
 
Discussion 
 
Previous study had reported that patients who were diagnosed of Paget disease with underlying 
invasive cancer had poor tumor characteristics15. A previous research showed that the Paget disease 
with underlying invasive cancer had tumors with Grade 3 histology8. In 1881, Thin observed that 
the nipple lesion contained malignant cells which were correlated to the underlying cancer16. And 
this observation suggested the process of intra ductal extension of cancer through the major 
lactiferous sinuses. We call it “Pagetoid spread” nowadays. Histologically, Paget cells are large 
cells with pale, clear cytoplasm. It has enlarged nucleoli located within the epidermis and along the 
basal layer. The most widely accepted hypothesis to explain the origin of Paget cells is the 
epidermotropic theory. And this theory considered that Paget cells are derived from an underlying 
mammary adenocarcinoma17. Evidence supporting the epidermotropic theory is based on studies 
showing that Paget disease is associated with an underlying breast carcinoma in most patients5, 18-20. 
Binding of heregulin to its receptor on Paget cells can induce chemotaxis of these breast cancer 
cells and the cells eventually migrate into the overlying nipple epidermis21. It is noteworthy that 
Paget cells and the underlying associated ductal carcinoma share the same immunohistochemical 
profile22
In allusion to different subtype of Paget disease, we found that the significant associated 
indicators were different. Unmarried patients of PD, including those who were windowed, divorced 
and never married were at significantly great risk of exist lymph node metastasis. Meanwhile, for 
patients of PD-IDC, we found that the hormone status was related with the human epidermal 
growth factor receptor II. However, for the PD-DCIS patients, only human epidermal growth factor 
receptor II had statistical significance. The association between marital status and these indicators 
was significant for every malignancy evaluated. Previous studies have linked marriage to 
 and the same patterns of gene expression. 
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improvements in cardiovascular, endocrine, and immune function and marriage may be a 
determinant of the magnitude and presence of this effect23, 24. Cortisol levels seem to be lower in 
patients with cancer who have adequate support networks, and diurnal cortisol patterns have been 
linked with natural-killer cell count and survival in patients with cancer25, 26, potentially providing a 
physiologic basis for the psychologically based data described previously27
 
. Further investigations 
on this subject are warranted. 
However, the study also had some limitations. The SEER database did not give us enough 
information about the lymphovascular invasion which can be regarded as the predict of lymph node 
metastasis. Besides, the follow-up of many patients was limited. And the information of systemic 
therapy of the patients was lack according the SEER system. Based on the SEER database, the 
HER2 status was tested from 2010, however the cases were from 2000 to 2013. Apparently, 
analyses of the HER2 was limited. And it made us unable to explore the clinical significance of 
HER2 status. Therefor our study was limited by lack of some information. Besides, there is 
potential for misclassification of marital status. We did not take into account changes of marital 
status which may have occurred during the follow-up period. And this phenomenon may have 
influenced our results. Thus, our findings may underestimate the protective effect that marriage has 
on breast cancer outcome. We defined that the single category contained divorcees, widows and 
never married women. However, previous studies had found that there may be some difference 
among groups of unmarried woman. Although the difference existed, the unmarried woman fare 
worse than the married counterparts. 
 
In conclusion, our study showed patients with PD-IDC have the worst prognosis. Among all 
these three kinds of Paget disease, unmarried patients had worse outcomes. And the marital status 
of PD-IDC patients is associated with hormone status and HER2 status. The observation 
underscores the importance of individualized treatment. 
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Materials and Methods 
Ethics Statement 
We obtained permission to access the SEER research data. The data downloaded from the 
SEER do not require informed patient consent. Besides, our research was approved by the Ethical 
Committee and Institutional Review of Fudan University Shanghai Cancer Center (FDUSCC). The 
methods were performed in accordance with the approved guidelines. 
 
Data source 
 
We examined the data from the National Cancer Institute’s Surveillance, Epidemiology, and 
End Results (SEER) program, which contains the population-based central cancer registries of 18 
geographically defined region. For this study, we use the November 2014-18 submission. 
 
Patient selection 
 
We use the histopathology codes from the International Classification of Disease for Oncology 
third edition (ICD-O-3) to select female patients. In the ICD-O-3, the codes are defined: code 8500 
(ductal carcinoma), code 8540 (mammary Paget disease), code 8541 (Paget disease with infiltrating 
ductal carcinoma), and code 8543 (Paget disease with intraductal carcinoma). According to the 
ICD-O-3, we defined and choose the patients who had the PD (ICD-O-3 code 8540/3), PD-IDC 
(ICD-O-3 code 85413), PD-DCIS (ICD-O-3 code 8543/3) and IDC (ICD-O-3 code 8500/3). In this 
study, women who were diagnosed as all three kinds of PD and ICD between 2000 and 2013 were 
included(n=501,631). And these identified patients included PD patients (n=469), PD-IDC 
patients(n=1832), PD-DCIS patients (n=1130) and infiltrating ductal carcinoma (IDC) (n=498,076). 
 
Statistical Analysis 
 
Overall survival (OS) was measured from the date on which the first time definite diagnosis 
was made until the date of death, the date last known to be alive or September 2013. Disease 
specific survival (DSS) was measured from the date of diagnosis to the date of death which is 
associated with breast carcinoma. The National Cancer Institute’s SEER*Stat software package 
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(version 6.1.4; built on April 13, 2005) was used to calculate incidence rates. Baseline patient 
demographic characteristics and tumor information were compared using the Pearson chi-square 
test for categorical variables. Survival curves were plotted according to the Kaplan-Meier method 
and compared using the log-rank test in a univariate analysis. Cox regression analysis was 
performed to compute hazard ratios and 95% confidence intervals (95% CIs) and to evaluate the 
effects of confounding factors. All the tests were two sided, and p values less than 0.05 were 
considered statistically significant. All the statistical analyses were performed using SPSS statistical 
software, version 22.0 (IBM Corp, Armonk, NY). 
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Table 1 Characteristics of patients with Paget Disease and infiltrating duct carcinoma 
 
 
 
Clinical Characteristics 
 
PD 
 
IDC 
 
 
PD-IDC 
 
IDC 
 PD- 
DCIS 
 
IDC 
 
N N P-value N N P-value N N P-value 
Age at 
diagnosis(years) 
18-49 114 158076 <0.001 665 158076 0.536 292 159076 <0.001 
 50-79 355 285894  1167 285894  838 285894  
Race White 393 360769 0.111 1446 360769 0.011 948 360769 0.069 
 Black 45 41277  206 41277  87 41277  
 Other 31 41924  180 41924  95 41924  
Marital status Married 216 243680 <0.001 903 243680 <0.001 561 243680 <0.001 
 Not 
married 
204 181155  856 181155  529 181155  
 Unknown 49 19134  73 19134  40 19134  
Laterality Left 237 224866 <0.001 959 224866 0.446 614 224866 0.066 
 Right 226 218611  872 218611  516 218611  
 Paired site 6 409  1 409  0 409  
 Unknown 0 84  0 84  0 84  
Tumor size(cm) <2 54 25463 <0.001 41 25463 <0.001 20 25463 <0.001 
 2.1-5 249 280120  1098 280120  672 280120  
 >5 9 7136  28 7136  6 7136  
 unknown 157 131251  665 131251  432 131251  
Lymph node 
status 
Negative 158 257428 <0.001 807 287428 <0.001 645 257428 0.539 
 Positive 311 186542  1025 186542  485 186542  
Grade I 11 84295 <0.001 113 84295 <0.001 17 84295 <0.001 
 II 23 176027  526 176027  108 176027  
 III 41 160309  1003 160309  396 160309  
 IV 3 5015  44 5015  237 5015  
 Unknown 391 18324  146 18324  372 18324  
AJCC stage 0 83 5 <0.001 4 5 <0.001 160 5 <0.001 
 I 11 70594  153 70594  19 70594  
 II 2 42900  106 42900  11 42900  
 III 4 13995  95 13995  3 13995  
 IV 3 6346  21 6346  1 6346  
 unknown 366 310130  1453 310130  936 310130  
ER status Negative 74 92846 <0.001 769 92846 <0.001 408 92846 <0.001 
 Positive 67 318298  849 318298  237 318298  
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 Borderline 0 701  11 701  1 701  
 Unknown 328 32125  203 32125  484 32125  
PR status Negative 95 136827 <0.001 983 136827 <0.001 467 136827 <0.001 
 Positive 37 268719  613 268719  138 268719  
 Borderline 0 2063  11 2063  2 2063  
 Unknown 337 36361  225 36361  523 36361  
HER2 status Negative 7 106696 <0.001 123 106696 <0.001 7 106696 <0.001 
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 Positive 17 21261  210 21261  33 21261  
 Borderline 0 3124  8 3124  3 3124  
 Unknown 445 312889  1491 312889  1087 312889  
Radiation NO 384 215199 <0.001 1348 215199 <0.001 918 215199 <0.001 
 YES 67 213217  435 213217  191 213217  
 Unknown 18 15554  49 15554  21 15554  
 
 
 
 
AJCC: American Joint Committee on Cancer, ER: oestrogen receptor, HER2: human epidermal growth factor receptor 2, IDC: 
infiltrating duct carcinoma, PD-IDC: Paget disease concomitant infiltrating duct carcinoma, PD-DCIS: Paget disease concomitant 
intraductal carcinoma, unmarried group included divorced, separated, single (never married) and windowed. 
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Table 2 The association between clinical characteristics of Paget disease and marital status 
 
Categories  PD 
  Married(n) Unmarried(n) Unknown(n) p-value 
Age at 
diagnosis(years) 
18-49 69 36 9 0.002 
 50-79 147 168 40  
Race White 187 170 36 0.027 
 Black 16 24 5  
 Other 13 10 8  
Laterality Left 109 113 15 0.004 
 Right 107 86 33  
 Paired site 0 5 1  
 Unknown 0 0 0  
Tumor size(cm) <2 16 25 13 <0.001 
 2.1-5 134 101 14  
 >5 0 5 4  
 unknown 66 73 18  
Lymph node status Negative 84 69 5 0.001 
 Positive 132 135 44  
Grade I 6 5 0 0.523 
 II 10 13 0  
 III 22 14 5  
 IV 2 1 0  
 Unknown 176 171 44  
AJCC stage 0 49 28 6 0.177 
 I 7 3 1  
 II 0 1 1  
 III 2 2 0  
 IV 2 1 0  
 unknown 156 169 41  
ER status Negative 33 34 7 0.249 
 Positive 38 26 3  
 Borderline 145 144 39  
 Unknown 216 204 49  
PR status Negative 48 39 8 0.641 
 Positive 18 17 2  
 Borderline 0 0 0  
 Unknown 150 148 39  
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HER2 status Negative 4 3 0 0.695 
 Positive 10 6 1  
 Borderline 0 0 0  
 Unknown 202 195 48  
Radiation NO 174 173 37 <0.001 
 YES 36 27 4  
 Unknown 6 4 8  
      
Categories PD-IDC 
  Married(n) Unmarried(n) Unknown(n) p-value 
Age at 
diagnosis(years) 
18-49 407 240 18 <0.001 
 50-79 496 616 55  
Race White 740 653 53 <0.001 
 Black 58 137 11  
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 Other 105 66 9  
Laterality Left 481 443 35 0.715 
 Right 422 412 38  
 Paired site 0 1 0  
 Unknown 0 0 0  
Tumor size(cm) <2 14 23 4 0.189 
 2.1-5 553 506 39  
 >5 14 14 0  
 unknown 322 313 30  
Lymph node status Negative 407 366 34 0.562 
 Positive 496 490 39  
Grade I 43 67 3 0.169 
 II 266 236 24  
 III 498 469 36  
 IV 25 18 1  
 Unknown 71 66 9  
AJCC stage 0 1 3 0 0.411 
 I 86 60 7  
 II 45 58 3  
 III 49 41 5  
 IV 13 8 0  
 unknown 709 686 58  
ER status Negative 397 347 25 0.01 
 Positive 424 391 34  
 Borderline 3 8 0  
 Unknown 79 110 14  
PR status Negative 492 456 35 0.006 
 Positive 314 279 20  
 Borderline 5 4 2  
 Unknown 92 117 16  
HER2 status Negative 56 63 4 0.025 
 Positive 114 88 8  
 Borderline 5 1 2  
 Unknown 728 704 59  
Radiation NO 634 660 45 <0.001 
 YES 244 174 17  
 Unknown 16 22 11  
      
Categories PD-IDC 
  Married(n) Unmarried(n) Unknown(n) p-value 
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Age at 
diagnosis(years) 
18-49 407 240 18 <0.001 
 50-79 496 616 55  
Race White 740 653 53 <0.001 
 Black 58 137 11  
 Other 105 66 9  
Laterality Left 481 443 35 0.715 
 Right 422 412 38  
 Paired site 0 1 0  
 Unknown 0 0 0  
Tumor size(cm) <2 14 23 4 0.189 
 2.1-5 553 506 39  
 >5 14 14 0  
 unknown 322 313 30  
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Lymph node status Negative 407 366 34 0.562 
 Positive 496 490 39  
Grade I 43 67 3 0.169 
 II 266 236 24  
 III 498 469 36  
 IV 25 18 1  
 Unknown 71 66 9  
AJCC stage 0 1 3 0 0.411 
 I 86 60 7  
 II 45 58 3  
 III 49 41 5  
 IV 13 8 0  
 unknown 709 686 58  
ER status Negative 397 347 25 0.01 
 Positive 424 391 34  
 Borderline 3 8 0  
 Unknown 79 110 14  
PR status Negative 492 456 35 0.006 
 Positive 314 279 20  
 Borderline 5 4 2  
 Unknown 92 117 16  
HER2 status Negative 56 63 4 0.025 
 Positive 114 88 8  
 Borderline 5 1 2  
 Unknown 728 704 59  
Radiation NO 634 660 45 <0.001 
 YES 244 174 17  
 Unknown 16 22 11  
 
 
AJCC: American Joint Committee on Cancer, ER: oestrogen receptor, HER2: human epidermal growth factor receptor 2, IDC: 
infiltrating duct carcinoma, PD-IDC: Paget disease concomitant infiltrating duct carcinoma, PD-DCIS: Paget disease concomitant 
intraductal carcinoma, unmarried group included divorced, separated, single (never married) and windowed. Au
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Table 3 Survival Analyses -Univariate Analyses of Paget disease 
 
PD   PD-IDC   PD-DCIS   
Variables Category p-value Variables Category p-value Variables Category p-value 
Age at 
diagnosis 
(years) 
18-49 <0.001 
Age at 
diagnosis 
(years) 
18-49 <0.001 
Age at 
diagnosis 
(years) 
18-49 <0.001 
 50-79   50-79   50-79  
Race White 0.052 Race White 0.296 Race White 0.253 
 Black   Black   Black  
 Other   Other   Other  
Marital 
status 
Married <0.001 Marital 
status 
Married <0.001 Marital 
status 
Married <0.001 
 Not married   Not married   Not married  
 Unknown   Unknown   Unknown  
Laterality Left 0.112 Laterality Left 0.561 Laterality Left 0.162 
 Right   Right   Right  
 Paired site   Paired site   Paired site  
 Unknown   Unknown   Unknown  
Tumor 
size(cm) 
<2 <0.001 Tumor 
size(cm) 
<2 <0.001 Tumor 
size(cm) 
<2 <0.001 
 2.1-5   2.1-5   2.1-5  
 >5   >5   >5  
 unknown   unknown   unknown  
Lymph 
node 
status 
Negative <0.001 Lymph 
node status 
Negative <0.001 Lymph 
node status 
Negative <0.001 
 Positive   Positive   Positive  
Grade I 0.069 Grade I 0.016 Grade I 0.313 
 II   II   II  
 III   III   III  
 IV   IV   IV  
 Unknown   Unknown   Unknown  
AJCC 
stage 
0 <0.001 AJCC stage 0 <0.001 AJCC stage 0 <0.001 
 I   I   I  
 II   II   II  
 III   III   III  
 IV   IV   IV  
 unknown   unknown   unknown  
ER status Negative 0.954 ER status Negative 0.004 ER status Negative 0.363 
 Positive   Positive   Positive  
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 Borderline   Borderline   Borderline  
 Unknown   Unknown   Unknown  
PR status Negative 0.758 PR status Negative 0.055 PR status Negative 0.565 
 Positive   Positive   Positive  
 Borderline   Borderline   Borderline  
 Unknown   Unknown   Unknown  
HER2 
status 
Negative 0.161 HER2 
status 
Negative 0.348 HER2 
status 
Negative <0.001 
 Positive   Positive   Positive  
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 Borderline   Borderline   Borderline  
 Unknown   Unknown   Unknown  
Radiation NO 0.085 Radiation NO 0.077 Radiation NO 0.007 
 YES   YES   YES  
 Unknown   Unknown   Unknown  
AJCC: American Joint Committee on Cancer, ER: oestrogen receptor, HER2: human epidermal growth factor receptor 2, IDC: 
infiltrating duct carcinoma, PD-IDC: Paget disease concomitant infiltrating duct carcinoma, PD-DCIS: Paget disease concomitant 
intraductal carcinoma, unmarried group included divorced, separated, single (never married) and windowed. 
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Table 4 Survival Analyses-Multivariate analyses of Paget disease 
 
PD     
Variables Category Hazard ratio 95% confidence 
interval 
p-value 
Age at diagnosis(years) 18-49 1 Referent 0.005 
 50-79 0.449 0.257-0.787  
Race White 1 Referent 0.014 
 Black 3.772 1.366-10.413  
 Other 5.495 1,756-17.2  
Marital status Married 1 Referent <0.001 
 Not married 0.379 0.214-0.672  
 Unknown 0.887 0.528-1.491  
Tumor size(cm) <2 1 Referent 0.033 
 2.1-5 1.417 0.806-2.494  
 >5 0.651 0.429-0.988  
 unknown 1.506 0.509-4.454  
Lymph node status Negative 1 Referent <0.001 
 Positive 0.417 0.264-0.658  
Grade I 1 Referent 0.042 
 II 1.065 0.3-2.86  
 III 2.537 1.239-5.139  
 IV 0.714 0.313-1.628  
 Unknown 1.404 0.189-10.436  
AJCC stage 0 1 Referent 0.203 
 I 0.795 0.353-1.793  
 II 0 0  
 III 0 0  
 IV 1.613 0.204-12.763  
 unknown 5.224 1.449-18.837  
     
PD-IDC     
Variables Category Hazard ratio 95% confidence 
interval 
p-value 
Age at diagnosis(years) 18-49 1 Referent <0.001 
 50-79 0.347 0.283-0.425  
Race White 1 Referent 0.77 
 Black 0.556 0.813-1.47  
 Other 0.472 0.795-1.643  
Marital status Married 1 Referent <0.001 
 Not married 0.625 0.427-0.914  
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 Unknown 1.053 0.728-1.523  
Tumor size(cm) <2 1 Referent <0.001 
 2.1-5 2.537 1.662-3.873  
 >5 0.915 0.769-1.088  
 unknown 1.255 0.685-2.302  
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Lymph node status Negative 1 Referent <0.001 
 Positive 0.437 0.366-0.522  
Grade I 1 Referent 0.049 
 II 0.696 0.439-1.103  
 III 0.946 0.683-1.311  
 IV 1.155 0.855-1.561  
 Unknown 0.855 0.705-2.256  
AJCC stage 0 1 Referent <0.001 
 I 0 0  
 II 0.548 0.256-1.172  
 III 0.67 0.329-1.364  
 IV 1.055 0.632-1.764  
 unknown 4.754 2.48-9.112  
ER status Negative 1 Referent 0.034 
 Positive 0.453 0.195-1.052  
 Borderline 0.438 0.19-1.007  
 Unknown 1.329 0.373-4.732  
PR status Negative 1 Referent 0.212 
 Positive 2.12 0.931-4.827  
 Borderline 1.818 0.799-4.138  
 Unknown 2.477 0.66-9.29  
     
PD-DCIS     
Variables Category Hazard ratio 95% confidence 
interval 
p-value 
Age at diagnosis(years) 18-49 1 Referent <0.001 
 50-79 0.309 0.203-0.469  
Race White 1 Referent 0.63 
 Black 1.058 0.619-1.808  
 Other 1.288 0.67-2.475  
Marital status Married 1 Referent <0.001 
 Not married 0.504 0.269-0.945  
 Unknown 1.237 0.675-2.266  
Tumor size(cm) <2 1 Referent <0.001 
 2.1-5 4.82 2.351-9.88  
 >5 1.035 0.772-1.388  
 unknown 1.617 0.218-11.983  
Lymph node status Negative 1 Referent <0.001 
 Positive 0.546 0.424-0.704  
Grade I 1 Referent 0.332 
 II 0.35 0.085-1.447  
 III 0.74 0.457-1.198  
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 IV 0.891 0.663-1.198  
 Unknown 0.786 0.569-1.088  
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ER status Negative 1 Referent 0.3 
 Positive 1.424 0.759-2.672  
 Borderline 0.922 0.486-1.749  
 Unknown 0.968 0.23-14.54  
PR status Negative 1 Referent 0.898 
 Positive 0.857 0.467-1.574  
 Borderline 1.047 0.513-2.134  
 Unknown 0 0  
HER2 status Negative 1 Referent 0.004 
 Positive 9.502 2.758-32.734  
 Borderline 0.614 0.084-4.466  
 Unknown 0 0  
Radiation NO 1 Referent 0.001 
 YES 2.183 0.688-6.922  
 Unknown 1.096 0.33-3.638  
AJCC: American Joint Committee on Cancer, ER: oestrogen receptor, HER2: human epidermal growth factor receptor 2, IDC: 
infiltrating duct carcinoma, PD-IDC: Paget disease concomitant infiltrating duct carcinoma, PD-DCIS: Paget disease concomitant 
intraductal carcinoma, unmarried group included divorced, separated, single (never married) and windowed. 
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Figure legends: 
Figure1 
According to the ICD-O-3, the codes are defined: code 8500 (ductal carcinoma), code 8540 
(mammary Paget disease), code 8541 (Paget disease with infiltrating ductal carcinoma), and code 
8543 (Paget disease with intraductal carcinoma). Overall survival (OS) was measured from the date 
on which the first time definite diagnosis was made until the date of death, the date last known to be 
alive or September 2013. 
 
Figure2 
According to the ICD-O-3, the codes are defined: code 8500 (ductal carcinoma), code 8540 
(mammary Paget disease), code 8541 (Paget disease with infiltrating ductal carcinoma), and code 
8543 (Paget disease with intraductal carcinoma). Disease specific survival (DSS) was measured 
from the date of diagnosis to the date of death which is associated with breast carcinoma. 
 
Figure3 
According to the Kaplan-Meier method and compared using the log-rank test, we analyzed the 
Paget disease and the marital status. 
a. The association between marital status and clinical prognosis in PD patients. 
b. The association between marital status and clinical prognosis in PD-IDC patients. 
c. The association between marital status and clinical prognosis in PD-DCIS patients. 
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